Work

Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC)

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw373.13

Authors: J. Bellmunt, S.A. Mullane, S. Jacobus, L. Polacek, D.Y. Takeda, L. Harshman, T. Choueiri, N. Wagle, E.M. Van Allen, P. Kantoff, J.E. Rosenberg

Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587948587

FWCI:

Cites:

Cited by:

Related to: 10